Hemostasis involves three sequential steps—vascular response, platelet adhesion and aggregation, and coagulation cascade—that form a clot. Disruption at any step causes either excessive bleeding or pathologic thrombosis.
Use flow diagrams to trace both intrinsic and extrinsic coagulation pathways. Study how tissue factor, phospholipid, and calcium initiate cascades. Understand feedback mechanisms: thrombin amplification and natural inhibitors.
Platelets do not directly activate—they require agonists (thrombin, ADP, collagen). The extrinsic pathway is not truly 'external'; tissue factor is released from damaged tissue. Fibrinolysis begins immediately, not after clot formation.
From your study of blood composition, you know that blood contains both cellular components (red cells, white cells, platelets) and plasma proteins (including clotting factors). Hemostasis is the coordinated process that prevents uncontrolled bleeding after vascular injury, and understanding its pathophysiology means understanding how failure at each step produces a distinct clinical syndrome.
The process unfolds in three overlapping phases. First, vascular response: damaged vessels constrict reflexively, reducing blood flow through the injured area and buying time for the next steps. Second, primary hemostasis: platelets adhere to exposed subendothelial matrix proteins (collagen, von Willebrand factor) via surface receptors, become activated — but critically, only when stimulated by agonists like thrombin, ADP, or collagen, not spontaneously — and aggregate into a soft platelet plug. This plug is mechanically fragile and must be reinforced. Third, secondary hemostasis: the coagulation cascade converts fibrinogen to fibrin, cross-linking the platelet plug into a stable, fibrin-reinforced clot.
The coagulation cascade has two initiating arms. The extrinsic pathway starts when tissue factor (exposed by vessel wall injury) binds to circulating Factor VIIa, forming a complex that rapidly activates downstream factors. The intrinsic pathway starts when Factor XII contacts exposed surfaces, triggering a slower cascade. Both converge on Factor X, which activates thrombin, which cleaves fibrinogen to fibrin and also amplifies platelet activation in a positive feedback loop. The designation "extrinsic" can mislead: tissue factor is released from damaged tissue inside the body, not from an external source.
Pathology arises from disruption in either direction. Too little hemostasis — from factor deficiencies (hemophilia A: Factor VIII deficiency), platelet disorders (von Willebrand disease, Glanzmann thrombasthenia), or anticoagulant medications — produces bleeding disorders. Too much hemostasis, or failure of the natural inhibitors (antithrombin, Protein C, Protein S), produces pathologic thrombosis — clots that form where they should not, or fail to dissolve. Crucially, fibrinolysis (clot dissolution by plasmin) begins at the same time as clot formation, not after: it is a simultaneous counter-process that limits clot extension and begins clearing the clot as healing proceeds.
Thinking about hemostasis disorders in terms of which step is defective helps organize clinical reasoning. Prolonged bleeding time with normal coagulation times suggests a platelet or vascular problem. Prolonged aPTT with normal platelet function suggests an intrinsic pathway factor deficiency. Prolonged PT with normal aPTT suggests an extrinsic pathway or common pathway defect (as in warfarin therapy, which depletes Vitamin K-dependent factors including VII). Each test illuminates a different segment of the cascade, and reading them together is how clinicians localize the problem.